# Annexon to Participate in Upcoming June Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ANNX/annexon-to-participate-in-upcoming-june-investor-conferences
Ticker: ANNX
Company: Annexon, Inc.
Source: Annexon, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.annexonbio.com
## Summary

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,

## Article Body
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,
## Recent Company News
- 2026-06-25 13:46 EST — [Annexon to Participate in Upcoming June Investor Conferences](https://biopharmsignal.com/news/ANNX/annexon-to-participate-in-upcoming-june-investor-conferences) — Source: Annexon, Inc.
- 2026-06-25 13:46 EST — [Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones](https://biopharmsignal.com/news/ANNX/annexon-reports-first-quarter-2026-financial-results-portfolio-progress-and-key-anticipated-milestones) — Source: Annexon, Inc.
- 2026-06-25 13:46 EST — [Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/ANNX/annexon-biosciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference) — Source: Annexon, Inc.
- 2026-06-25 13:46 EST — [Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome](https://biopharmsignal.com/news/ANNX/annexon-submits-tanruprubart-marketing-authorization-application-to-the-european-medicines-agency-for-guillain-barre-syndrome) — Source: Annexon, Inc.
- 2026-06-25 13:46 EST — [Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026](https://biopharmsignal.com/news/ANNX/annexon-accelerating-next-generation-targeted-immunotherapy-platform-for-treatment-of-neuroinflammatory-diseases-with-multiple-registrational-milestones-in-2026) — Source: Annexon, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)